| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Strategy Officer
1 company
Prior Stephen David is a Chief Strategy Officer at AN2 Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 4 sells.
Estimated insider holdings value: $272K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | ANTX An2 Therapeutics, Inc. | Chief Strategy Officer | Sell | 6,462 | $1.01 | $6,507.11 | -5.1% | +215.0% | - | |
| Nov 4, 2025 | ANTX An2 Therapeutics, Inc. | Chief Strategy Officer | Sell | 765 | $1.14 | $872.10 | -1.2% | -1.8% | - | |
| Jan 3, 2025 | ANTX An2 Therapeutics, Inc. | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2,720.89 | -5.7% | -1.4% | -21.8% |